Quince Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $33.2M
- Price
- $33.93
- % Change (Daily % change from the live per-ticker quote feed.)
- +5.67%
- Volume
- 9.5K
About
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Quick stats
Shares outstanding978.0K
Computed float763.7K
Float / shares78.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001662774
Websitehttps://www.quincetx.com
AI Summary
AI-generated1/10
majorbullishearnings
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Quince Therapeutics reported Q2 financial results highlighted by the completion of the Orphai Therapeutics acquisition and a $115 million private placement financing.
The company ended the quarter with $116 million in cash, which is expected to fund operations through the end of 2028, supporting the development of the LAM-001 pipeline.
Management also announced the execution of 1-for-10 and 1-for-20 reverse stock splits in April and June, respectively, and anticipates Phase 2 data for LAM-001 in BOS in Q1 2027 and PH-ILD in Q1 2028.
Red flags
- Reverse stock splits of 1-for-10 and 1-for-20 effected to maintain listing compliance
- Significant non-cash charge of $59 million for acquired in-process R&D
- G&A expenses increased 5x year-over-year due to acquisition costs